AbbVie, Teva Pay-For-Delay Deal Draws More Antitrust Claims
AbbVie Inc. and Teva Pharmaceutical Industries Ltd. were sued Tuesday in Pennsylvania federal court over a patent settlement that allegedly delayed market entry of a generic form of AbbVie's Niaspan cholesterol...To view the full article, register now.
Already a subscriber? Click here to view full article